These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7686209)

  • 1. Leishmania major-specific, CD4+, major histocompatibility complex class II-restricted T cells derived in vitro from lymphoid tissues of naive mice.
    Shankar AH; Titus RG
    J Exp Med; 1993 Jul; 178(1):101-11. PubMed ID: 7686209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.
    Sadick MD; Locksley RM; Tubbs C; Raff HV
    J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-gamma inhibits the efficacy of interleukin 1 to generate a Th2-cell biased immune response induced by Leishmania major.
    Wagner HM; Beuscher HU; Röllinghoff M; Solbach W
    Immunobiology; 1991 Jun; 182(3-4):292-306. PubMed ID: 1680802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity.
    Titus RG; Müller I; Kimsey P; Cerny A; Behin R; Zinkernagel RM; Louis JA
    Eur J Immunol; 1991 Mar; 21(3):559-67. PubMed ID: 1672641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells.
    Müller I; Pedrazzini T; Kropf P; Louis J; Milon G
    Int Immunol; 1991 Jun; 3(6):587-97. PubMed ID: 1909563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
    Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
    J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis.
    Scott P
    J Immunol; 1991 Nov; 147(9):3149-55. PubMed ID: 1833466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice.
    Locksley RM; Reiner SL; Hatam F; Littman DR; Killeen N
    Science; 1993 Sep; 261(5127):1448-51. PubMed ID: 8367726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell and non-T cell compartments can independently determine resistance to Leishmania major.
    Shankar AH; Titus RG
    J Exp Med; 1995 Mar; 181(3):845-55. PubMed ID: 7869047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease.
    Chakkalath HR; Theodos CM; Markowitz JS; Grusby MJ; Glimcher LH; Titus RG
    J Infect Dis; 1995 May; 171(5):1302-8. PubMed ID: 7751707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.
    Scott P; Natovitz P; Coffman RL; Pearce E; Sher A
    J Exp Med; 1988 Nov; 168(5):1675-84. PubMed ID: 2903212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.
    Scharton TM; Scott P
    J Exp Med; 1993 Aug; 178(2):567-77. PubMed ID: 8101861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.
    Yang DM; Rogers MV; Liew FY
    Immunology; 1991 Jan; 72(1):3-9. PubMed ID: 1997399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy between activated Leishmania major-specific CD4+ T lymphocytes and bone-marrow-derived cells in the exacerbation of murine cutaneous leishmaniasis.
    Mendonça SC; Titus RG; Louis JA
    Res Immunol; 1990; 141(9):865-78. PubMed ID: 1983098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major.
    Doherty TM; Coffman RL
    J Immunol; 1993 Jun; 150(12):5476-83. PubMed ID: 8515072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.
    Reiner SL; Zheng S; Wang ZE; Stowring L; Locksley RM
    J Exp Med; 1994 Feb; 179(2):447-56. PubMed ID: 7905017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.
    Radwanska M; Cutler AJ; Hoving JC; Magez S; Holscher C; Bohms A; Arendse B; Kirsch R; Hunig T; Alexander J; Kaye P; Brombacher F
    PLoS Pathog; 2007 May; 3(5):e68. PubMed ID: 17500591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin 12 cures mice infected with Leishmania major.
    Heinzel FP; Schoenhaut DS; Rerko RM; Rosser LE; Gately MK
    J Exp Med; 1993 May; 177(5):1505-9. PubMed ID: 8097524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some cloned murine CD4+ T cells recognize H-2Ld class I MHC determinants directly. Other cloned CD4+ T cells recognize H-2Ld class I MHC determinants in the context of class II MHC molecules.
    McKisic MD; Sant AJ; Fitch FW
    J Immunol; 1991 Nov; 147(9):2868-74. PubMed ID: 1717578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.